HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.

AbstractThe treatment of acute promyelocytic leukemia (APL) has been based on the administration of all-trans retinoic acid plus anthracycline chemotherapy, which is very effective as first line therapy; however 25 to 30% of patients will relapse with their disease becoming refractory to conventional therapy. Recently, studies have shown arsenic trioxide to be effective in the treatment of acute promyelocytic leukemia. In this study, we used the human leukemia (HL-60) cell line as a model to evaluate the cytoxicity of arsenic trioxide based on the MTT assay. Data obtained from this assay indicated that arsenic trioxide significantly reduced the viability of HL-60 cells, showing LD50 values of 14.26 + 0.5microg/mL, 12.54 + 0.3microg/mL, and 6.4 + 0.6microg/mL upon 6, 12, and 24 hours of exposure, respectively; indicating a dose- and time-dependent response relationship. Findings from the present study indicate that arsenic trioxide is highly cytotoxic to human leukemia (HL-60) cells, supporting its use as an effective therapeutic agent in the management of acute promyelocytic leukemia.
AuthorsClement G Yedjou, Pamela Moore, Paul B Tchounwou (Affiliation: Molecular Toxicology Research Laboratory, NIH-RCMI Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, P.O. Box 18540, Jackson, Mississippi, USA.)
JournalInternational journal of environmental research and public health (Int J Environ Res Public Health) Vol. 3 Issue 2 Pg. 136-40 (Jun 2006) ISSN: 1661-7827 [Print] Switzerland
PMID16823087 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • arsenic trioxide
Topics
  • Antineoplastic Agents (pharmacology)
  • Arsenicals (pharmacology)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • HL-60 Cells
  • Humans
  • Leukemia (drug therapy)
  • Oxides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD